The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

The 200 mg/mL subcutaneous autoinjection therapy is a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal antibody which can be administered at home and offers more flexibility and ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

Belimumab autoinjector is now approved and available for pediatric patients with lupus nephritis. The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for ...

The FDA has approved Benlysta for SC administration using an autoinjector in patients 5 years of age and older with active LN.

The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years and above with active lupus nephritis (LN), who are currently receiving ...

These are called autoantibodies. In a 2015 study in the journal Arthritis and Rheumatology, a group of Canadian researchers ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

The FDA has approved Gamifant as the first-ever treatment for macrophage activation syndrome in Still’s disease for adults ...

Gamifant marks the first-ever FDA-approved treatment for both adult and pediatric patients with hemophagocytic ...